MK-2206, an allosteric pan-Akt inhibitor, shows synergistic activity with cytotoxic compounds such as doxorubicin, gemcitabine, docetaxel and carboplatin in lung cancer.75 In addition, MK-2206 inhibits the phosphorylation of Akt mediated by carboplatin and gemcitabine, thereby enhancing the therapeutic effect of the drug by inhibiting tumor survival laterally.210 MK-2206 also enhances erlotinib activity in erlotinib-sensitive patients and erlotinib-resistant NSCLC cell lines.211 Recently, MK-2206 entered preclinical studies to determine its effects on acute myeloid leukemia (AML). Here, AKT1 is linked to neoplasm.